1. Home
  2. BRAI vs RCUS Comparison

BRAI vs RCUS Comparison

Compare BRAI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRAI

Braiin Limited Common Stock

N/A

Current Price

$12.49

Market Cap

2.6B

Sector

N/A

ML Signal

N/A

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$25.32

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRAI
RCUS
Founded
N/A
2015
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.9B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BRAI
RCUS
Price
$12.49
$25.32
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$31.90
AVG Volume (30 Days)
494.7K
788.7K
Earning Date
N/A
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$247,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$45.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.62
$7.92
52 Week High
$32.32
$28.72

Technical Indicators

Market Signals
Indicator
BRAI
RCUS
Relative Strength Index (RSI) 53.64 57.35
Support Level $12.56 $23.91
Resistance Level $27.42 $26.70
Average True Range (ATR) 1.82 1.10
MACD 1.19 -0.02
Stochastic Oscillator 49.45 84.53

Price Performance

Historical Comparison
BRAI
RCUS

About BRAI Braiin Limited Common Stock

Braiin Ltd is an Australian technology company leveraging proprietary intellectual property and patented artificial intelligence/machine learning (AI/ML) technologies to deliver actionable insights across the verticals: Agriculture, Property Technology, and Customer Experience as a Service (CXaaS). The company's platforms are designed to address inefficiencies and drive data-backed decision-making across traditionally analog sectors. It prominently focuses on the agriculture technology sector, where it has successfully deployed its AI-powered solutions across multiple implementations. It provides end-to-end solutions to improve farming productivity using IoTs, Wireless Connectivity, Robotics, Software and AI/ML.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Share on Social Networks: